Ovarian metastasis from non‑small cell lung cancer with ALK and EGFR mutations: A report of two cases

Mushi,Rosemary T.; Yang,Yumei; Cai,Qian; Zhang,Ruiguang; Wu,Gang; Dong,Xiaorong

doi:10.3892/ol.2016.5292

Ovarian metastasis from non‑small cell lung cancer with ALK and EGFR mutations: A report of two cases

Authors:
- Rosemary T. Mushi
- Yumei Yang
- Qian Cai
- Ruiguang Zhang
- Gang Wu
- Xiaorong Dong
View Affiliations

Affiliations: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China, Department of Respiratory Medicine, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430000, P.R. China
Published online on: October 19, 2016 https://doi.org/10.3892/ol.2016.5292
Pages: 4361-4366
Copyright: © Mushi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian metastasis from non‑small cell lung cancer (NSCLC) is a rare condition. The current study presents the cases of 2 female patients aged 38 and 47 years old, respectively, who were initially diagnosed with NSCLC adenocarcinoma on histology. Both patients initially presented with chest pain and a cough, and subsequently developed ovarian metastases following multiple treatments. The 38‑year old patient exhibited an epidermal growth factor receptor mutation, confirmed by scorpion/amplified refractory mutation system analysis from a lung biopsy. The 47‑year old exhibited an anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement, revealed by fluorescence in situ hybridization analysis of the breast tissue biopsy, confirming a diagnosis of ALK rearrangement‑positive NSCLC. These patients developed ovarian metastasis in the course of the disease. The current study reports the diagnostic challenges and clinical management of the disease, and provides a review of the literature.

View Figures

View References

1	Rial M Botana, Fernández-Villar A, González Piñeiro A and Leiro Fernandez V: Primary lung adenocarcinoma with ovarian metastasis: A rare presentation of bronchogenic carcinoma. Arch Bronconeumol. 45:571–572. 2009.(In Spanish). View Article : Google Scholar : PubMed/NCBI
2	Islami F, Torre LA and Jemal A: Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 4:327–338. 2015.PubMed/NCBI
3	Irving JA and RH Y: Lung carcinoma metastatic to the ovary: A clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol. 29:997–1006. 2005.PubMed/NCBI
4	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
5	Young RH and Scully RE: Ovarian metastases from cancer of the lung: Problems in interpretation - a report of seven cases. Gynecol Oncol. 21:337–350. 1985. View Article : Google Scholar : PubMed/NCBI
6	Vang R and Ronnett BM: Metastatic and miscellaneous primary tumors of the ovaryGynecologic Pathology. Nucci MR and Oliva E: Elsevier Churchill Livingstone; Philadelphia: pp. 539–614. 2009, View Article : Google Scholar
7	Kim K, Cho SY, Park SI, Kang HJ, Kim BJ, Kim MH, Choi SC, Ryu SY and Lee ED: Risk of metastatic ovarian involvement in nongynecologic malignancies. Int J Gynecol Cancer. 22:3–8. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shi Y, Ye D, Lu W, Zhao C, Xu J and Chen L: Histological classification in 10 288 cases of ovarian malignant tumors in China. Zhonghua Fu Chan Ke Za Zhi. 37:97–100. 2002.(In Chinese). PubMed/NCBI
9	American Joint Committee on Cancer, . Lung Cancer Staging. 7th edition. http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.pdfAccessed March 7, 2015.
10	Yeh KY, Chang JW, Hsueh S, Chang TC and Lin MC: Ovarian metastasis originating from bronchioloalveolar carcinoma: A rare presentation of lung cancer. Jpn J Clin Oncol. 33:404–407. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ordóñez NG: Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol. 7:123–127. 2000. View Article : Google Scholar : PubMed/NCBI
12	Suzuki A, Shijubo N, Yamada G, Ichimiya S, Satoh M, Abe S and Sato N: Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract. 201:579–586. 2005. View Article : Google Scholar : PubMed/NCBI
13	Bishop JA, Sharma R and Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 41:20–25. 2010. View Article : Google Scholar : PubMed/NCBI
14	Soria JC, Mok TS, Cappuzzo F and Jänne PA: EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat Rev. 38:416–430. 2012. View Article : Google Scholar : PubMed/NCBI
15	Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
16	Solomon B, Varella-Garcia M and Camidge DR: ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 4:1450–1454. 2009. View Article : Google Scholar : PubMed/NCBI
17	Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 99:2349–2355. 2008. View Article : Google Scholar : PubMed/NCBI
18	Horn L and Pao W: EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
19	Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
20	XALKORI^®: (crizotinib) (package insert). Pfizer, NY: 2012, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s002lbl.pdf
21	Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
22	Fujiwara A, Higashiyama M, Kanou T, Tokunaga T, Okami J, Kodama K, Nishino K, Tomita Y and Okamoto I: Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement. Lung Cancer. 83:302–304. 2014. View Article : Google Scholar : PubMed/NCBI